Uterine leiomyomas: Individualizing the approach to a heterogeneous condition

Obstetrics and Gynecology

Volumn 117, Issue 2 PART 1, 2011, Pages 396-403

  Laughlin, Shannon K ^a   Stewart, Elizabeth A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GADOLINIUM; PROGESTERONE; TRANEXAMIC ACID; TUBERIN;

AFRICAN AMERICAN; ARTICLE; CONTRAST ENHANCEMENT; ENDOMETRIUM ABLATION; EVIDENCE BASED PRACTICE; FEMALE; FEMALE FERTILITY; HUMAN; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; MYOMECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENICITY; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT PLANNING; TUMOR GROWTH; UTERINE ARTERY EMBOLIZATION; UTERUS MYOMA; VAGINA RING;

FEMALE; FERTILITY; HUMANS; LEIOMYOMA; UTERINE NEOPLASMS; UTERUS;

EID: 79251591016     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31820780e3     Document Type: Article

References (60)

1. Speert H. Obstetrics and gynecology in America: a history. Chicago (IL): American College of Obstetricians and Gynecologists; 1980.
2. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 2002;99:229-34.
3. Jacobson GF, Shaber RE, Armstrong MA, Hung YY. Hysterectomy rates for benign indications. Obstet Gynecol 2006;107: 1278-83.
4. Merrill RM. Hysterectomy surveillance in the United States 1997 through 2005. Med Sci Monit 2008, 14:CR24-31.
5. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100-7.
6. Laughlin SK, Baird DD, Savitz DA, Herring AH, Hartmann KE. Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasound-screening study. Obstet Gynecol 2009;113:630-5.
7. Eskenazi B, Warner M, Samuels S, Young J, Gerthoux PM, Needham L, et al. Serum dioxin concentrations and risk of uterine leiomyoma in the Seveso Women's Health Study. Am J Epidemiol 2007;166:79-87.
8. Huyck KL, Panhuysen CI, Cuenco KT, Zhang J, Goldhammer H, Jones ES, et al. The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters. Am J Obstet Gynecol 2008;198: 168.e1-9.
9. Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med 1996;41:483-90.
10. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997;90:967-73.
11. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988-1990. Obstet Gynecol 1994;83:549-55.
12. Ishikawa H, Reierstad S, Demura M, Rademaker AW, Kasai T, Inoue M, et al. High aromatase expression in uterine leiomyoma tissues of African-American women. J Clin Endocrinol Metab 2009;94:1752-6.
13. Pan Q, Luo X, Chegini N. Genomic and proteomic profiling I: leiomyomas in African Americans and Caucasians. Reprod Biol Endocrinol 2007;5:34.
14. Wamsteker K, Emanuel MH, de Kruif JH. Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension. Obstet Gynecol 1993;82:736-40.
15. Peddada SD, Laughlin SK, Miner K, Guyon JP, Haneke K, Vahdat HL, et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci USA 2008;105:19887-92.
16. Aharoni A, Reiter A, Golan D, Paltiely Y, Sharf M. Patterns of growth of uterine leiomyomas during pregnancy. A prospective longitudinal study. Br J Obstet Gynaecol 1988;95:510-3.
17. Rosati P, Exacoustos C, Mancuso S. Longitudinal evaluation of uterine myoma growth during pregnancy. A sonographic study. J Ultrasound Med 1992;11:511-5.
18. Laughlin SK, Herring AH, Savitz DA, Olshan AF, Fielding JR, Hartmann KE, et al. Pregnancy-related fibroid reduction. Fertil Steril 2010;94:2421-3.
19. Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology 2003;14:247-50.
20. Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004;159:113-23.
21. Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998;70:432-9.
22. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994;83:414-8.
23. Alternatives to hysterectomy in the management of leiomyo-mas. ACOG Practice Bulletin. American College of Obstetricians and Gynecologists. Obstet Gynecol 2008;112:387-400.
24. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science 2005;308:1589-92.
25. Stewart EA. Uterine fibroids: the complete guide. Baltimore (MD): Johns Hopkins University Press; 2007.
26. Yoshida S, Ohara N, Xu Q, Chen W, Wang J, Nakabayashi K, et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 2010;28:260-73.
27. Stewart EA, Morton CC. The genetics of uterine leiomyomata: what clinicians need to know. Obstet Gynecol 2006;107: 917-21.
28. Rein MS, Powell WL, Walters FC, Weremowicz S, Cantor RM, Barbieri RL, et al. Cytogenetic abnormalities in uterine myomas are associated with myoma size. Mol Hum Reprod 1998;4:83-6.
29. Brosens I, Deprest J, Dal Cin P, Van den Berghe H. Clinical significance of cytogenetic abnormalities in uterine myomas. Fertil Steril 1998;69:232-5.
30. Hodge JC, Park PJ, Dreyfuss JM, Assil-Kishawi I, Soma-sundaram P, Semere LG, et al. Identifying the molecular signature of the interstitial deletion 7q subgroup of uterine leiomyomata using a paired analysis. Genes Chromosomes Cancer 2009;48:865-85.
31. Malik M, Norian J, McCarthy-Keith D, Britten J, Catherino WH. Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin Reprod Med 2010;28:169-79.
32. Stewart EA, Nowak RA. New concepts in the treatment of uterine leiomyomas. Obstet Gynecol 1998;92:624-7.
33. Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update 1996;2:295-306.
34. Lee BS, Nowak RA. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab 2001;86:913-20.
35. Leppert PC, Catherino WH, Segars JH. A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol 2006;195: 415-20.
36. Malik M, Webb J, Catherino WH. Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells. Clin Endocrinol (Oxf) 2008;69:462-70.
37. Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 1998;83: 219-23.
38. Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Sharan C, Rajaratnam V, et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol 2010;202:289.e1-9.
39. Blauer M, Rovio PH, Ylikomi T, Heinonen PK. Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro. Fertil Steril 2009;91:1919-25.
40. Faerstein E, Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: a practice-based casecontrol study. II. Athero-genic risk factors and potential sources of uterine irritation. Am J Epidemiol 2001;153:11-9.
41. Laughlin SK, Schroeder JC, Baird DD. New directions in the epidemiology of uterine fibroids. Semin Reprod Med 2010;28: 204-17.
42. Viswanathan M, Hartmann K, McKoy N, Stuart G, Rankins N, Thieda P, et al. Management of uterine fibroids: an update of the evidence. Evid Rep Technol Assess (Full Rep) 2007;154: 1-122.
43. Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, March-banks PA, Curtis KM. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010; 82:41-55.
44. Lakhani KP, Marsh MS, Purcell W, Hardiman P. Uterine artery blood flow parameters in women with dysfunctional uterine bleeding and uterine fibroids: the effects of tranexamic acid. Ultrasound Obstet Gynecol 1998;11:283-5.
45. Sundstrom A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranex-amic acid and other drugs used to treat menorrhagia: a casecontrol study using the General Practice Research Database. BJOG 2009;116:91-7.
46. Ip PP, Lam KW, Cheung CL, Yeung MC, Pun TC, Chan QK, et al. Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas. Am J Surg Pathol 2007;31:1215-24.
47. El-Nashar SA, Hopkins MR, Creedon DJ, St Sauver JL, Weaver AL, McGree ME, et al. Prediction of treatment outcomes after global endometrial ablation. Obstet Gynecol 2009;113:97-106.
48. Tanaka YO, Nishida M, Tsunoda H, Okamoto Y, Yoshikawa H. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings. J Magn Reson Imaging 2004;20:998-1007.
49. Bedient CE, Magrina JF, Noble BN, Kho RM. Comparison of robotic and laparoscopic myomectomy. Am J Obstet Gynecol 2009;201:566.e1-5.
50. van der Kooij SM, Hehenkamp WJ, Volkers NA, Birnie E, Ankum WM, Reekers JA. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 5-year outcome from the randomized EMMY trial. Am J Obstet Gynecol 2010;203:105.e1-13.
51. Edwards RD, Moss JG, Lumsden MA, Wu O, Murray LS, Twaddle S, et al. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med 2007;356: 360-70.
52. Smeets AJ, Nijenhuis RJ, van Rooij WJ, Weimar EA, Boekkooi PF, Lampmann LE, et al. Uterine artery embolization in patients with a large fibroid burden: long-term clinical and MR follow-up. Cardiovasc Intervent Radiol 2010;33:943-8.
53. Katsumori T, Kasahara T, Tsuchida Y, Nozaki T. Amenorrhea and resumption of menstruation after uterine artery embolization for fibroids. Int J Gynaecol Obstet 2008;103:217-21.
54. Stewart EA, Gostout B, Rabinovici J, Kim HS, Regan L, Tempany CM. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol 2007;110: 279-87.
55. Hartmann KE, Birnbaum H, Ben-Hamadi R, Wu EQ, Farrell MH, Spalding J, et al. Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol 2006;108:930-7.
56. Lee DW, Ozminkowski RJ, Carls GS, Wang S, Gibson TB, Stewart EA. The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids. J Occup Environ Med 2007;49:493-506.
57. Pritts EA. Fibroids and infertility: a systematic review of the evidence. Obstet Gynecol Surv 2001;56:483-91.
58. Pron G, Mocarski E, Bennett J, Vilos G, Common A, Vander-burgh L. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Obstet Gynecol 2005;105:67-76.
59. Hehenkamp WJ, Volkers NA, Broekmans FJ, de Jong FH, Themmen AP, Birnie E, et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod 2007;22:1996-2005.
60. Rabinovici J, David M, Fukunishi H, Morita Y, Gostout BS, Stewart EA. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertil Steril 2010;93:199-209.